A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) (MYSTIC)
A study for patients with advanced Non-Small-Cell Lung Cancer (NSCLC) using study drug MEDI4736 in combination with Tremelimumab
Sponsor: AstraZeneca
Enrolling: Male and Female Patients
IRB Number: AAAP9838
U.S. Govt. ID: NCT02453282
Contact: Naiyer Rizvi: 212-305-1945 / nar2144@columbia.edu
Additional Study Information: The purpose of this study is to evaluate the combination of MEDI4736 and tremelimumab in treating non-small cell lung cancer. This study will look to see whether MEDI4736 combined with tremelimumab or MEDI4736 alone are more effective than standard of care chemotherapy in treating lung cancer and to collect information on the safety of these drugs. Both MEDI4736 and tremelimumab may help the immune system to slow down or stop tumor growth. Participants will be assigned to receive either MEDI4736 in combination with tremelimumab, MEDI4736 alone, or standard of care chemotherapy during the treatment period.
This study is closed
Do You Qualify?
Have you been diagnosed with Non-Small-Cell Lung Cancer? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Naiyer Rizvi